bluebird bio (BLUE) Rating Reiterated by JPMorgan Chase & Co.

bluebird bio (NASDAQ:BLUE)‘s stock had its “buy” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research report issued on Thursday.

Several other brokerages also recently commented on BLUE. BidaskClub downgraded bluebird bio from a “sell” rating to a “strong sell” rating in a research report on Tuesday, October 23rd. Oppenheimer restated a “hold” rating on shares of bluebird bio in a research report on Tuesday, November 27th. Raymond James started coverage on bluebird bio in a research report on Wednesday, December 19th. They set a “strong-buy” rating and a $165.00 price objective on the stock. Goldman Sachs Group cut bluebird bio from a “conviction-buy” rating to a “buy” rating in a research report on Friday, September 21st. Finally, Morgan Stanley lowered their price objective on bluebird bio from $190.00 to $186.00 and set an “equal weight” rating on the stock in a research report on Monday, October 15th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. bluebird bio presently has a consensus rating of “Buy” and a consensus price target of $188.83.

NASDAQ BLUE traded down $1.61 during trading on Thursday, hitting $115.28. The company’s stock had a trading volume of 405,728 shares, compared to its average volume of 574,441. The company has a market cap of $6.03 billion, a P/E ratio of -14.95 and a beta of 2.41. bluebird bio has a 52 week low of $87.49 and a 52 week high of $236.17.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.90) by $0.17. The company had revenue of $11.50 million for the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.73) EPS. Sell-side analysts expect that bluebird bio will post -10.76 earnings per share for the current year.

In related news, insider David Davidson sold 7,600 shares of the business’s stock in a transaction on Thursday, January 3rd. The stock was sold at an average price of $98.82, for a total value of $751,032.00. Following the sale, the insider now owns 15,559 shares of the company’s stock, valued at approximately $1,537,540.38. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Susanna Gatti High sold 1,890 shares of the business’s stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $113.83, for a total value of $215,138.70. Following the completion of the sale, the chief operating officer now directly owns 15,610 shares in the company, valued at approximately $1,776,886.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,777 shares of company stock worth $3,290,502. 3.00% of the stock is currently owned by company insiders.

Hedge funds have recently made changes to their positions in the stock. Casdin Capital LLC boosted its stake in bluebird bio by 37.9% in the 2nd quarter. Casdin Capital LLC now owns 200,000 shares of the biotechnology company’s stock valued at $31,390,000 after buying an additional 55,000 shares in the last quarter. Xact Kapitalforvaltning AB boosted its stake in bluebird bio by 17.7% in the 3rd quarter. Xact Kapitalforvaltning AB now owns 8,630 shares of the biotechnology company’s stock valued at $1,260,000 after buying an additional 1,300 shares in the last quarter. Bank of America Corp DE boosted its stake in bluebird bio by 26.6% in the 2nd quarter. Bank of America Corp DE now owns 155,890 shares of the biotechnology company’s stock valued at $24,467,000 after buying an additional 32,724 shares in the last quarter. Vident Investment Advisory LLC boosted its stake in bluebird bio by 37.0% in the 2nd quarter. Vident Investment Advisory LLC now owns 13,501 shares of the biotechnology company’s stock valued at $2,119,000 after buying an additional 3,643 shares in the last quarter. Finally, Credit Suisse AG boosted its stake in bluebird bio by 26.6% in the 3rd quarter. Credit Suisse AG now owns 259,738 shares of the biotechnology company’s stock valued at $37,921,000 after buying an additional 54,498 shares in the last quarter.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

See Also: What is the Quick Ratio?

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply